Intravascular large B-cell lymphoma (IVLBCL) is a rare and deadly malignancy involving the growth of lymphoma cells within vessel lumina of all organ types. IVLBCL is further divided into the hemophagocytic Asian variant and a classical Western variant. Both variants are difficult to diagnose by imaging, and although diagnostic criteria have been developed to guide workup, histopathological examination remains imperative. Treatment of IVLBCL remains difficult given the high mortality of the disease, but rituximab has emerged as a promising therapeutic option when combined with various cytotoxic regimens. The two main variants of IVLBCL generally manifest in their respective Asian or Western populations, and crossover between ethnicities is rare. We present the second described case of Asian-variant IVLBCL in an African American individual.
I ntravascular large B-cell lymphoma (IVLBCL) is a rare large B-cell lymphoma that often has a poor clinical outcome (1) . Despite its propensity to involve all organ types in a diff use vascular growth pattern, IVLBCL is diffi cult to diagnose due to the lack of overt lymphadenopathy and peripheral blood involvement (2) (3) (4) (5) . Asian and Western variants of IVLBCL share similar features, but generally diff er in presentation (5) . We present a rare case of Asian-variant IVLBCL in a black man.
CASE PRESENTATION
A 69-year-old black man with coronary artery disease and chronic kidney disease presented to an outside facility with 2 weeks of B symptoms. He had no smoking, tobacco, or illicit drug history and was active and functional prior to these symptoms. His pertinent travel history included military service in Vietnam during the Vietnam War. He had no known family history of malignancies and no known Asian family ancestry. After initially leaving against medical advice, he presented to another facility where he developed refractory hypotension and fevers, acute-on-chronic kidney disease progressing to end-stage renal disease requiring hemodialysis, and progressive pancytopenia. An extensive workup ruled out many bacterial, fungal, parasitic, viral, and atypical infections, and a bone marrow biopsy revealed no infection, tuberculosis, or evidence of malignancy. Th rombotic thrombocytopenic purpura was ruled out by peripheral blood smear examination and ADAMTS13 testing. Given the patient's progressive deterioration and lack of etiology for his fevers, he was transferred to our facility for a higher level of care.
On transfer, his temperature was 39.2°C (102.6°F); pulse rate, 122 beats per minute; and systolic blood pressure, 70 mm Hg. He had mild bilateral upper lobe wheezing, epigastrium tenderness, and marked pretibial pitting edema in the lower extremities bilaterally. Th ere was no skin rash or hepatosplenomegaly. Laboratory studies revealed leukocytosis of 11.2 × 10 3 /μL (range 3.8-10.8) with a neutrophil predominance, a hemoglobin of 9.2 g/dL (range 13. Th e patient was treated with broad-spectrum antibiotics and antifungals, continuous renal replacement therapy for refractory hypotension, and intubation for progressive altered mentation and inability to protect the airway. Computed tomography disclosed hepatomegaly (24 cm), splenomegaly (14 cm), bilateral nephromegaly (right kidney 13 cm, left kidney 15 cm), and bilateral adrenal enlargement without evidence of a focal mass. A serum protein electrophoresis was negative for paraproteins, and a peripheral blood leukemia and lymphoma fl ow cytometry panel identifi ed predominantly mature T cells with fewer NK cells and polyclonal B cells, but no clonal population. Bone marrow biopsy showed a mildly hypocellular marrow with trilineage Asian-variant intravascular large B-cell lymphoma Derrick W. Su, MD, Whitney Pasch, DO, Cristina Costales, MD, Imran Siddiqi, MD, and Ann Mohrbacher, MD cardia and vasopressor-refractory shock, worsening acidosis, and shock liver. On hospital day 7, the family opted for comfortoriented care, and shortly after palliative extubation, the patient died.
Autopsy disclosed the spleen to weigh 500 g (normal 150-200 g) and liver 2750 g (normal ≤1700 g) but found no discrete masses, enlarged lymph nodes, or skin lesions. Microscopic examination revealed widespread, multiorgan capillary infi ltration by enlarged, atypical lymphocytes. Organs involved included vessels throughout the brain and brainstem, lungs, vaso vasorum of the aorta, epicardiac and cardiac vessels, kidneys, adrenal glands, gastrointestinal tract, psoas muscle, gallbladder, pancreas, urinary bladder, spleen, liver, and bone marrow (Figures 1 and 2 ). Immunohistochemical stains showed the atypical intravascular lymphocytes to be immunoreactive for CD5, CD20, Bcl-2 (focally positive), and MUM1 (subset) and negative for Bcl-1, Bcl-6, CD10, and CD30. Th e bone marrow also revealed extensive CD68+ hemophagocytic histiocytes (Figure 2) . Th e fi nal diagnosis and cause of death was IVLBCL with hemophagocytic syndrome and multiple organ failure.
DISCUSSION
IVLBCL is classifi ed by the World Health Organization as a rare type of extranodal large B-cell lymphoma characterized by the selective growth of lymphoma cells within vessel lumina-particularly capillaries-with the exception of large arteries and veins. Historically, 53% of patients are diagnosed on autopsy (1) . IVLBCL involves all organ types, including bone hematopoiesis, mild megakaryocytic hyperplasia, and rare hemophagocytic cells. As the patient met criteria for hemophagocytic lymphohistiocytosis (HLH), he was started on dexamethasone 10 mg/m 2 intravenously (6). Unfortunately, prior to etoposide administration, the patient developed supraventricular tachy- marrow, central nervous system, spleen, liver, gastrointestinal tract, adrenal glands, skin, and others, though lymphadenopathy is usually absent (2-4). Despite its diff use vasculature growth pattern, peripheral blood involvement is seen in only 5% to 9% of patients (5).
The two distinct variants of IVLBCL-a hemophagocytic Asian variant and a classical Westernvariant-were described through examination of patient case series in Japan (4, 7) and Italy (2), respectively (Table 1) (5). Both variants appear to aff ect men and women equally and present with B symptoms. Central nervous system involvement is manifested by heterogeneous symptoms of sensory and motor defi cits, seizures, vertigo, and altered mentation and is more common in the Western variant (2, 7). Th e Asian variant more frequently involves the liver, spleen, and bone marrow, while skin involvement occurs more often in the Western variant (2, 7) . Th e Asian variant IVLBCL is also strongly associated with HLH (7), whereas HLH is not typically seen in the Western variant (2, 8) . Skin lesions vary widely in morphology and distribution and are commonly located in the upper arms and legs, low abdomen, and breast (2) . Interestingly, the Asian variant is rarely seen outside of Asian patient populations. To date, there have only been occasional case reports of IVLBCL with hemophagocytic syndrome in Caucasian patients (9, 10) and only one other case report of Asian-variant IVLBCL in a patient of African descent (11) .
Diagnostic criteria for Asianvariant IVLBCL have been proposed; these are summarized in Table 2 (4, 12) . Workup of IVLBCL should include a search for suspicious cutaneous lesions for biopsy, peripheral blood smear, and routine blood tests. Given anecdotal reports of cerebrospinal fluid involvement, lumbar puncture with cerebrospinal fl uid examination is recommended, whereas bone marrow biopsy may reveal lymphomatous or hemophagocytic (5) cells. Contrasted whole-body computed tomography as well as contrasted magnetic resonance imaging of the brain are also suggested, though a high level of false-negative results has been reported (5). [ 18 F]fl uorodeoxyglucose positron emission tomography also carries a high false-negative rate for IVLBCL, with only a 29% detection rate of pathologically confi rmed lesions (13) , likely due to the diff use nature of IVLBCL and lack of adenopathy contributing to a lower volume of regional tumor. Random skin biopsies of the abdomen and extremities may also be an option in the workup of IVLBCL, with a small series showing a 36% rate of diagnosis (14) . IVLBCL cells are large, with increased nuclear-to-cytoplasmic ratios, irregular nuclear contours, hyperchromatic, condensed chromatin with occasionally prominent nucleoli, and scant cytoplasm. Mitotic fi gures are markedly increased, and Ki-67 staining is usually above 50%. By immunohistochemistry, IVLBCL is virtually always immunoreactive for CD20 and CD79a (7) (Figure 1) . Interestingly, the lymphoma cells lack cell surface proteins critical to lymphocyte transvascular migration, which is thought to contribute to a defi ciency in the ability to migrate out of the microvasculature (15, 16) .
Th e introduction of rituximab has dramatically improved the outcome of IVLBCL. In one of the largest retrospective studies on IVLBCL treatment, patients receiving rituximabbased chemotherapy regimens had longer progression-free survivals and overall survivals compared to patients receiving non-rituximab-based therapies (2-year progression-free survival of 56% vs. 27% and 2-year overall survival of 66% vs. 46% for rituximab-based vs. chemotherapy alone groups, respectively) (17), with chemotherapy being predominantly cyclophosphamide, vincristine, doxorubicin, and prednisolone (CHOP) or CHOP-like regimens. Other studies have also demonstrated improved complete remission and survival rates with rituximabbased regimens in the Western variant (18) , and there have even been reports of single-agent rituximab inducing long-term remission in disease refractory to anthracycline-based therapy (19) . Th e choice of specifi c cytotoxic chemotherapeutics in IVLBCL is less clear, particularly in the setting of disease associated with HLH. While etoposide-based regimens have been used successfully for HLH (6) , there are no studies to date on the use of the HLH-94 protocol in the treatment of IVLBCL.
